Century Therapeutics, Inc. (IPSC)
Largest Insider Buys in Sector
IPSC Stock Price History Chart
IPSC Stock Performance
About Century Therapeutics, Inc.
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, …
Insider Activity of Century Therapeutics, Inc.
Over the last 12 months, insiders at Century Therapeutics, Inc. have bought $7,657 and sold $381,816 worth of Century Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Century Therapeutics, Inc. have bought $16M and sold $2.7M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Quimi Daphne (director) — $22,971.
The last purchase of 5,000 shares for transaction amount of $7,657 was made by Quimi Daphne (director) on 2024‑09‑12.
List of Insider Buy and Sell Transactions, Century Therapeutics, Inc.
| 2024-11-04 | Sale | SVP Finance & Operations | 283 0.0003% | $1.23 | $347 | +10.32% | ||
| 2024-11-04 | Sale | Chief Operations Officer | 1,033 0.0012% | $1.23 | $1,267 | +10.32% | ||
| 2024-09-12 | director | 5,000 0.0059% | $1.53 | $7,657 | -4.87% | |||
| 2024-08-05 | Sale | SVP Finance & Operations | 289 0.0003% | $1.83 | $528 | -17.20% | ||
| 2024-08-05 | Sale | Chief Operations Officer | 1,073 0.0012% | $1.83 | $1,960 | -17.20% | ||
| 2024-07-26 | Sale | See Remarks | 586 0.0007% | $2.50 | $1,465 | -38.00% | ||
| 2024-07-24 | Sale | See Remarks | 1,600 0.002% | $2.52 | $4,029 | -5.50% | ||
| 2024-07-23 | Sale | See Remarks | 200 0.0002% | $2.50 | $500 | -4.80% | ||
| 2024-06-20 | Sale | See Remarks | 5,000 0.0052% | $2.84 | $14,179 | -41.64% | ||
| 2024-06-05 | Sale | See Remarks | 5,000 0.006% | $3.00 | $14,989 | -45.97% | ||
| 2024-05-20 | Sale | See Remarks | 5,000 0.006% | $3.00 | $14,978 | -44.63% | ||
| 2024-05-06 | Sale | See Remarks | 5,000 0.0076% | $3.12 | $15,619 | -46.69% | ||
| 2024-05-03 | Sale | SVP Finance & Operations | 257 0.0004% | $3.11 | $798 | -43.89% | ||
| 2024-05-03 | Sale | Chief Operations Officer | 913 0.0014% | $3.11 | $2,836 | -43.89% | ||
| 2024-04-22 | Sale | See Remarks | 5,000 0.0078% | $3.10 | $15,490 | -44.34% | ||
| 2024-03-07 | Sale | Chief Operations Officer | 22,831 0.0373% | $5.14 | $117,342 | -55.26% | ||
| 2024-03-06 | Sale | Chief Operations Officer | 30,684 0.0503% | $4.96 | $152,340 | -51.90% | ||
| 2024-02-16 | Sale | Chief Operations Officer | 485 0.0008% | $4.86 | $2,358 | -43.19% | ||
| 2024-02-06 | Sale | SVP Finance & Operations | 557 0.001% | $4.49 | $2,499 | -36.92% | ||
| 2024-02-06 | Sale | Chief Operations Officer | 1,784 0.0031% | $4.49 | $8,005 | -36.92% |
Insider Historical Profitability
| Quimi Daphne | director | 5000 0.0059% | $1.10 | 1 | 0 | |
| BAYER AKTIENGESELLSCHAFT | 10 percent owner | 12675838 14.9077% | $1.10 | 1 | 0 | <0.0001% |
| Casdin Eli | director | 3206380 3.7709% | $1.10 | 1 | 0 | <0.0001% |
| Versant Venture Capital VI, L.P. | 10 percent owner | 714095 0.8398% | $1.10 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Vr Adviser Llc | $14.23M | 4.03 | 3.41M | New | +$14.23M | 0.69 | |
| Fidelity Investments | $14.09M | 3.99 | 3.37M | -6.68% | -$1.01M | <0.01 | |
| Casdin Capital | $13.4M | 3.79 | 3.21M | 0% | +$0 | 0.66 | |
| Boxer Capital, LLC | $7.32M | 2.07 | 1.75M | New | +$7.32M | 0.15 | |
| BlackRock | $6.26M | 1.77 | 1.5M | -1.37% | -$87,006.71 | <0.0001 |